Amgen: Anemia trials

The registry lists 48 Anemia studies with Amgen as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 4Phase 2 16Phase 3 18Phase 4 7No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving HemodialysisCompletedNCT02253654Phase 4Results posted
• TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin BetaCompletedNCT01997892Results posted
• Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving HemodialysisTerminatedNCT01737879Phase 4Results posted
• Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaCompletedNCT01444456Results posted
• Darbepoetin Alfa and Anemia of CancerTerminatedNCT00989092Phase 2Results posted
• Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney DiseaseCompletedNCT00925587Phase 3Results posted
• Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyTerminatedNCT00858364Phase 3Results posted
• LEARN-6™: A Prospective, Observational Nursing Home StudyCompletedNCT00727571Results posted
• Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney DiseaseTerminatedNCT00436748Phase 3Results posted
• A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)CompletedNCT00431496Phase 4Results posted
• Darbepoetin Alfa With or Without Intravenous (IV) IronCompletedNCT00401544Phase 2Results posted
• STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) PatientsTerminatedNCT00364845Phase 3Results posted
• RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialCompletedNCT00358215Phase 3Results posted
• Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive TherapyWithdrawnNCT05323617Phase 2
• A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing ChemotherapyCompletedNCT03776032Phase 3
• Study of Haemodialysis Patients Switching From Aranesp to BiosimilarCompletedNCT02191150
• Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on DialysisCompletedNCT02185911
• Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney DiseaseWithdrawnNCT01428154Phase 1
• Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle ChemotherapyCompletedNCT00540384Phase 1/2
• An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) TrialTerminatedNCT00534456Phase 3
• Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid MalignanciesCompletedNCT00239239Phase 2
• Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.CompletedNCT00148421Phase 3
• Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving HemodialysisCompletedNCT00146224Phase 3
• Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to ChemotherapyCompletedNCT00144131Phase 2
• Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney DiseaseCompletedNCT00121602Phase 3
• Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to ChemotherapyCompletedNCT00121030Phase 2
• Treatment for Patients Suffering From Anemia Due to ChemotherapyCompletedNCT00120692Phase 2
• Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to ChemotherapyCompletedNCT00120679Phase 2
• A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle ChemotherapyTerminatedNCT00119600Phase 1/2
• Darbepoetin Alfa Treatment of Anemia in Hemodialysis SubjectsCompletedNCT00119587Phase 3
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyCompletedNCT00118638Phase 3
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid MalignancyCompletedNCT00117624Phase 3
• A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control SubjectsCompletedNCT00117247Phase 1/2
• Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and AnemiaCompletedNCT00117234Not applicable
• A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®CompletedNCT00117117Phase 4
• Study of Transplant Related Anemia Treated With Aranesp® (STRATA)CompletedNCT00117065Phase 4
• A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With AnemiaCompletedNCT00117039Phase 4
• A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 StudyCompletedNCT00115167Phase 3
• Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving HemodialysisCompletedNCT00111995Phase 4
• Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle ChemotherapyCompletedNCT00111462Phase 2
• Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyCompletedNCT00110955Phase 3
• Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving DialysisCompletedNCT00096915Phase 3
• Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of CancerCompletedNCT00095277Phase 2
• Study of Darbepoetin Alfa for the Treatment of Anemia of CancerCompletedNCT00091858Phase 3
• Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & AnemiaCompletedNCT00086086Phase 2
• Heart Failure and AnemiaCompletedNCT00049985Phase 2
• Anemia in Patients With a Non-Myeloid MalignancyCompletedNCT00038064Phase 3
• Chemotherapy Related AnemiaCompletedNCT00035607Phase 2